Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Katy MarshallUpper Tract Urothelial Carcinoma | February 28, 2024
Patients in the POUT trial were randomized to either a platinum-based adjuvant chemotherapy arm or a surveillance arm.
Read More
Katy MarshallMuscle Invasive Urothelial Carcinoma | February 15, 2024
Data from 458 patients who underwent RC between October 2005 and October 2020 and 146 in the PURE-01 trial was analyzed.
Thomas Powles, MBBS, MRCP, MDAdvanced Urothelial Carcinoma | February 13, 2024
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Vadim Koshkin, MDUrothelial Carcinoma | February 12, 2024
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
Emily MenendezAdvanced Urothelial Carcinoma | February 12, 2024
With a high response rate and manageable toxicity, further research into the use of SG in patients with mUC is warranted.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | February 8, 2024
The guidelines included recommendations for treatment with TURBT and postoperative intravesical chemotherapy.
Emily MenendezProstate Cancer | February 12, 2024
The quality of patient-reported outcome analyses over the past 15 years is unknown, as reporting has waned.
Katy MarshallUpper Tract Urothelial Carcinoma | February 7, 2024
Researchers investigated the ability of variant histology to predict oncological outcomes.
Karine Tawagi, MDUrothelial Carcinoma | February 8, 2024
Dr. Tawagi provides her thoughts on treatment selection and sequencing for mUC, especially after progression on EV/pembro.
Vadim Koshkin, MDUrothelial Carcinoma | February 8, 2024
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
Vadim Koshkin, MDUrothelial Carcinoma | February 8, 2024
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
Vadim Koshkin, MDUrothelial Carcinoma | February 8, 2024
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
Vadim Koshkin, MDUrothelial Carcinoma | February 8, 2024
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
Vadim Koshkin, MDUrothelial Carcinoma | February 8, 2024
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
Vadim Koshkin, MDUrothelial Carcinoma | February 8, 2024
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
Vadim Koshkin, MDUrothelial Carcinoma | February 8, 2024
The panel discussed how enfortumab vedotin and pembrolizumab figures to change the bladder cancer treatment landscape.
Sia Daneshmand, MDASCO GU Symposium 2024 | February 6, 2024
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
Advertisement
Advertisement
Advertisement